DAVITA (DVA) 10-K Summary — Year Ended Dec 31, 2024
DaVita Inc. operates kidney dialysis services and related healthcare businesses. The filing reports annual revenue growth and positive operating cash flow, while outlining several operational and regulatory risks.
Key takeaway
Year ended Dec 31, 2024 · FY2025 10-K
DaVita Inc. operates kidney dialysis services and related healthcare businesses. The filing reports annual revenue growth and positive operating cash flow, while outlining several operational and regulatory risks.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$12.8B
Revenue reported for the fiscal year.
Operating income
$2.1B
Income from operations reported for the year.
Net income
$936.3M
Net income reported for the year.
Operating cash flow
$2B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $11.6B | n/a |
| Dec 31, 2022 | $11.6B | -0.1% |
| Dec 31, 2023 | $12.1B | +4.6% |
| Dec 31, 2024 | $12.8B | +5.6% |
Business overview
DaVita is a provider of kidney dialysis services for patients with chronic kidney failure or end-stage renal disease. The company also offers related healthcare services through its integrated care and pharmacy operations. Its business is primarily conducted in the United States.
Financial performance
Revenue increased compared to the prior year, while operating income and net income were reported at levels consistent with the company's scale. Operating cash flow remained positive, supporting ongoing operations.
Material risks
The filing identifies risks related to changes in government reimbursement rates for dialysis services, which could affect revenue. It also notes potential impacts from regulatory changes, including healthcare laws and data privacy requirements. Additionally, the company faces competition and operational risks in its dialysis and related healthcare segments.
Liquidity and capital
The company generated sufficient operating cash flow to fund its capital expenditures and debt service obligations. Capital allocation priorities include reinvestment in the business and managing debt levels.
What to watch
Investors should monitor any changes in government dialysis reimbursement policies in the next filing.